White Paper: Induced Pluripotent Stem Cell (iPSC) Based Therapies

Current pre-clinical approaches to characterizing iPSC-based therapies may miss significant genomic and transcriptomic heterogeneity. Read our perspective on how emerging single-cell multiomics technologies put more comprehensive data in researchers’ hands.

In this white paper, you'll read about:

• The genomic and transcriptomic heterogeneity in iPSC culture and reprogramming
• Why single-cell multiomic analysis is necessary to characterize and validate iPSC-based therapeutic candidates
• Tools that make it possible to precisely, sensitively detect insertions, deletions, substitutions, larger genomic alterations, alternative splicing events, and altered gene expression across the entire genome – and attribute these variants to individual cells.